<DOC>
	<DOCNO>NCT00439660</DOCNO>
	<brief_summary>This study Phase I , randomize , double blind , safety immunogenicity trial Vero cell base 116E neonatal rotavirus vaccine candidate strain healthy non-malnourished infant age 8-20 week three different dosage level i.e.10^4.0 , 10^5.0 10^6.0 FFU three administration dosages give infant 4-week interval . 180 infant ( 90 vaccinees/90 placebo ) enrol three dosage level . The progression lower next high dosage base approval Data Safety Monitoring Board ( DSMB ) constitute Department Biotechnology , New Delhi .</brief_summary>
	<brief_title>Dose Escalation Study Evaluate Oral Rotavirus Vaccine 116E Live Attenuated Healthy Infants 8 20 Weeks Old</brief_title>
	<detailed_description>Infants identify community survey urban neighborhood city Delhi , India screen 6 week age parental consent available . They give first dose EPI vaccine age . Of screened , eligible infant give first administration test vaccine/placebo 8 week age meet enrollment inclusion criterion , consent available . The safety profile study daily home visit 14 day post administration . Stool specimens collect vaccination ( day 0 ) day 3 , 7 28 post administration vaccine/placebo . Subsequently , two contact make ; home visit day 21 clinic visit day 28 . On day 28 visit , stool blood specimen collect . Prior administration vaccine/placebo infant assess contraindication . All screen infant offer EPI vaccine schedule . The second third administration study vaccine/placebo 12 16 week age strategy follow three dosage The study vaccine/placebo administer EPI vaccine even though future rotavirus vaccine EPI vaccine may coadministered . For purpose study schedule adopt , data available interaction EPI vaccine rotavirus vaccine candidate . Baseline serum collect 6 week ( time screen ) 4 week administration vaccine/placebo randomly select subsample first ( 60 infant ) , second ( 60 infant ) third ( 60 infant ) administration dosage . Clinical adverse event monitor relatedness vaccine/placebo administration assess 14 day administration dosage study , whereas monitoring symptom intussusception assess throughout 28 day follow period . Laboratory adverse event monitor upto 28 day first administration dosage . After 4 week follow third administration vaccine/placebo low dosage ( 10^4.0 ) complete enrolled infant data safety monitor board ( DSMB ) meeting convene data study analyze , code broken . If DSMB declare dosage safe , guide apriori criterion , team move screen infant next high dosage ( 10^5.0 ) strategy list repeat total 180 enrolled infant ( 90 vaccinees/90 placebo ) . The DSMB meet review data available cohort ( i.e . 10^5.0 ) team proceed screen infant next high dosage ( 10^6.0 ) former declare safe . At end study i.e . last visit last participant , base reactogenicity immunogenicity profile dosage , appropriate dosage select clinical evaluation .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Access telephone home immediate neighborhood . 2 . Healthy male female nonmalnourished ( weight length ≤ 3 SD WHO child growth standard ) infant age 6 week ( till 6 week + 2 day ) . 3 . Parent ’ permission participate study available . 4 . No plan travel next 4 month 1 . Gestational age &lt; 37 week . 2 . Any major physical congenital malformation . 3 . Living household contact individual immunosuppressed . 4 . Hospitalized follow illness since birth : heart disease , pneumonia , sepsis , meningitis , unconsciousness . 5 . Is required take daily medication vitamin herbal “ tonic ” . 6 . Evidence cardiovascular disease indicate follow : Central cyanosis Cyanotic apnoeic spell Features congestive heart failure Significant heart murmur detect physical examination 7 . Evidence gastrointestinal disease indicate follow : Diarrhea previous 7 day Blood stool time since birth 8 . Evidence neurological disease , indicate : History seizure time since birth History unconsciousness Focal deficit physical examination 9 . Evidence liver reticuloendothelial disease , indicate following : Positive serology hepatitis B surface antigen Positive serology hepatitis C antibody SGOT SGPT 1.25 time upper limit normal ( Upper limit normal SGOT 80 IU/L , SGPT 40 IU/L ) Alkaline phosphatase 1.25 time upper limit normal ( Upper limit normal 470 IU/L ) Hepatomegaly ( liver palpable 3 cm costal margin ) , splenomegaly ( palpable spleen ) , jaundice , lymphadenopathy physical examination Serum bilirubin 1.25 time upper limit normal age ( Upper limit normal 1.0 mg/dL ) . 10 . Evidence hematologic , rheumatologic , immunologic disease , indicate following : Total leukocyte count &lt; 3500 &gt; 15,000/mm3 Hemoglobin &lt; 9 g/dL &gt; 17g/dL Platelet count &lt; 100,000/mm3 Any episode sepsis , pneumonia meningitis require hospitalization since birth . 11 . Evidence renal disease indicate follow : Creatinine &gt; 0.5 mg/dL Hematuria ( ≥5 RBC/hpf ) Proteinuria ( ≥1+ per day )</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>20 Weeks</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Rotavirus , diarrhea , vaccine</keyword>
</DOC>